TherapeuticsMD (TXMD) Misses Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 Financial Results
March 2, 2021 7:00 AM EST- Full-year 2020 total net product revenue increased 84% to $62.9 million compared to 2019 -
- 4Q20 total net product revenue increased 30% to $22.6 million compared to 3Q20 -
- ANNOVERA® net product revenue increased 42% for 4Q20 compared to 3Q20 -
- Financing Agreement amended to update minimum net revenue covenants for remainder of loan; Company to pay down $50 million in debt -
- vitaCare divesture progressing with multiple interested parties -
- Conference call scheduled for 8:30 a.m. ET today -
BOCA RATON,... More
